Ipsen – Option agreement to acquire Canbex Therapeutics – Businesswire

Ipsen will complement its portfolio with the acquisition of the UK biotech, Canbex Therapeutics

MS_and_the_Brain_DamageCanbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R (Phase I successfully completed). As stated by Marc de Garidel, Chairman and CEO of Ipsen, “it could be a valuable companion product to Dysport® in the treatment of spasticity”. Read more